PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30904073-0	2019	Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.	Sofosbuvir	28-38	BMP binding endothelial regulator	Homo sapiens	85-90
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	Sofosbuvir	187-197	interferon lambda 3	Homo sapiens	16-34
30431653-0	2019	Polymorphism in interferon lambda3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	Sofosbuvir	187-197	interferon lambda 3	Homo sapiens	35-50
30683552-2	2019	Some compounds exhibited potent anti-HCV activities, such as 4e and 8a-8c with similar EC50 values (0.20-0.22 muM) comparative to that of sofosbuvir (EC50 = 0.18 muM) in a genotype 1b based replicon Huh-7 cell line.	Sofosbuvir	138-148	latexin	Homo sapiens	162-165
30383478-0	2018	Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.	Sofosbuvir	60-70	interferon lambda 3	Homo sapiens	20-26
30375710-15	2019	CONCLUSION: Successful sofosbuvir-based AVT leads to a variety of positive development in transplant patients including a significant improvement of inflammation, fat content and fibrosis, a significant decrease in daily insulin dose and no significant impairment of kidney function.	Sofosbuvir	23-33	insulin	Homo sapiens	221-228
30791790-4	2018	For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy.	Sofosbuvir	69-79	cAMP responsive element modulator	Homo sapiens	38-42
30791790-4	2018	For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy.	Sofosbuvir	81-84	cAMP responsive element modulator	Homo sapiens	38-42
30098373-14	2018	LAY SUMMARY: In phase III studies, 12 weeks of treatment with the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) cured 97% of patients with hepatitis C virus who failed prior treatment with direct-acting antiviral drugs.	Sofosbuvir	81-91	small integral membrane protein 1 (Vel blood group)	Homo sapiens	127-130
30141214-9	2018	Patients with GT1 and GT3 treated with sofosbuvir/ribavirin (SR) had 88% and 89% SVR12, respectively, but those GT6 treated with sofosbuvir/ledipasvir (SL) had only 77.6% SVR12.	Sofosbuvir	39-49	beta-1,4-galactosyltransferase 1	Homo sapiens	14-17
30556034-2	2018	Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	41-44
30288771-4	2018	RESULTS: SOF/VEL/VOX is positioned as a salvage regimen for patients previously treated with NS5A inhibitors and for genotype 1a- and 3-infected patients who had failed other sofosbuvir-containing regimens.	Sofosbuvir	175-185	small integral membrane protein 1 (Vel blood group)	Homo sapiens	9-20
30253037-0	2018	Association of IL-1beta, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients.	Sofosbuvir	100-110	estrogen receptor 1	Homo sapiens	37-41
29569712-2	2018	The objective of this study was to determine if these relationships could be utilized to predict transporter induction by other CYP3A inducers (rifabutin and carbamazepine) and of another P-gp substrate, sofosbuvir.	Sofosbuvir	204-214	ATP binding cassette subfamily B member 1	Homo sapiens	188-192
29569712-6	2018	Induction of P-gp, CYP2C9, and decreased sofosbuvir exposure were successfully predicted by observed CYP3A induction.	Sofosbuvir	41-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-106
30384188-7	2018	Bioanalytical method validation as per EMA guidelines was carried out where the proposed method revealed linearity over the concentration range of 5-5000 and 10-1500 ng mL-1 for sofosbuvir and velpatasvir, respectively.	Sofosbuvir	178-188	L1 cell adhesion molecule	Mus musculus	169-173
30425548-5	2018	We estimated the FGF21 levels at the start of the study for all the participants and for the patients only at the end of treatment with simisipivir (SIM) and sofosbuvir (SOF).	Sofosbuvir	158-168	fibroblast growth factor 21	Homo sapiens	17-22
30425548-5	2018	We estimated the FGF21 levels at the start of the study for all the participants and for the patients only at the end of treatment with simisipivir (SIM) and sofosbuvir (SOF).	Sofosbuvir	170-173	fibroblast growth factor 21	Homo sapiens	17-22
29665069-1	2018	BACKGROUND: Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) for hepatitis C virus (HCV) in patients with or without human immunodeficiency virus (HIV) coinfection.	Sofosbuvir	96-106	small integral membrane protein 1 (Vel blood group)	Homo sapiens	108-111
29886154-1	2018	BACKGROUND & AIMS: Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no anticipated clinically relevant drug-drug interactions with immunosuppressants.	Sofosbuvir	23-33	small integral membrane protein 1 (Vel blood group)	Homo sapiens	104-107
28795238-2	2018	AIM: To study the efficacy and safety of sofosbuvir-based, IFN-free antiviral therapy in chronic HCV patients with rheumatologic EHM.	Sofosbuvir	41-51	interferon alpha 1	Homo sapiens	59-62
30145562-1	2018	INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF).	Sofosbuvir	185-195	beta-1,4-galactosyltransferase 1	Homo sapiens	89-92
30145562-1	2018	INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF).	Sofosbuvir	197-200	beta-1,4-galactosyltransferase 1	Homo sapiens	89-92
29314090-1	2018	A simple and highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method was developed and fully validated for the first time for the simultaneous determination of newly discovered antiviral drugs, namely sofosbuvir (SOF) and daclatasvir (DAC) in human plasma.	Sofosbuvir	253-256	dachshund family transcription factor 1	Mus musculus	275-278
29684978-4	2018	Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12).	Sofosbuvir	65-75	lipocalin 2	Homo sapiens	27-31
30600949-7	2018	Circulating Th17 cells and serum IL17 levels were significantly decreased after successful Sofosbuvir-Ribavirin therapy (P < 0.0001).	Sofosbuvir	91-101	interleukin 17A	Homo sapiens	33-37
29522085-0	2018	Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.	Sofosbuvir	220-230	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-21
29452294-3	2018	We evaluated the impact of polymorphisms in genes (CYP27B1, CYP24A1, VDBP and VDR) related to vitamin D pathway on sofosbuvir and GS-331007 plasma levels in HCV mono-infected patients at one month of treatment.	Sofosbuvir	115-125	GC vitamin D binding protein	Homo sapiens	69-73
29452294-3	2018	We evaluated the impact of polymorphisms in genes (CYP27B1, CYP24A1, VDBP and VDR) related to vitamin D pathway on sofosbuvir and GS-331007 plasma levels in HCV mono-infected patients at one month of treatment.	Sofosbuvir	115-125	vitamin D receptor	Homo sapiens	78-81
29509884-1	2018	Background: Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate.	Sofosbuvir	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	122-127
29509884-1	2018	Background: Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate.	Sofosbuvir	12-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	187-192
29509884-3	2018	Objectives: In this work, we investigated the association between sofosbuvir and its prevalent metabolite (GS-331007) plasma concentrations at 1 month of therapy and genetic variants (SNPs) in genes encoding transporters and nuclear factors (ABCB1, ABCG2 and HNF4alpha) related to sofosbuvir transport.	Sofosbuvir	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	242-247
29509884-3	2018	Objectives: In this work, we investigated the association between sofosbuvir and its prevalent metabolite (GS-331007) plasma concentrations at 1 month of therapy and genetic variants (SNPs) in genes encoding transporters and nuclear factors (ABCB1, ABCG2 and HNF4alpha) related to sofosbuvir transport.	Sofosbuvir	281-291	ATP binding cassette subfamily B member 1	Homo sapiens	242-247
29509884-10	2018	Conclusions: In this study we suggested sofosbuvir GS-331007 metabolite plasma levels were affected by variants in the ABCB1 and HNFalpha genes.	Sofosbuvir	40-50	ATP binding cassette subfamily B member 1	Homo sapiens	119-124
29484572-11	2018	CONCLUSION: Low-dose Sofosbuvir and full-dose Daclatasvir are safe and effective in treating CHC in patients with CKD with eGFR less than 30 mL/min/1.73 m2.	Sofosbuvir	21-31	CD59 molecule (CD59 blood group)	Homo sapiens	144-149
29374597-4	2018	Therefore, we examined the association of GHRL gene polymorphisms (rs26312 and rs27647), and its serum level to virologic responses to combined sofosbuvir and Simeprevir therapy for a course of 12 successive weeks in Egyptian chronic hepatitis C (CHC) patients.	Sofosbuvir	144-154	ghrelin and obestatin prepropeptide	Homo sapiens	42-46
29077864-0	2018	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.	Sofosbuvir	17-27	KRAS proto-oncogene, GTPase	Homo sapiens	154-157
28972699-3	2018	Ledipasvir along with Sofosbuvir has been approved for management of genotype 1 infection in patients with eGFR >=30 mL/min.	Sofosbuvir	22-32	epidermal growth factor receptor	Homo sapiens	107-111
29077864-11	2018	Conclusions: Our findings support the concept of retreating with sofosbuvir + grazoprevir/elbasvir + ribavirin, for 16 weeks, genotype 1 or 4 DAA-experienced patients with proven NS5A or NS3 RASs.	Sofosbuvir	65-75	KRAS proto-oncogene, GTPase	Homo sapiens	187-190
28884930-1	2018	AIM: To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-beta injections was formulated according to the types of resistance-associated substitutions (RAS) in the non-structural protein (NS)5A region of genotype 1b hepatitis C virus (HCV).	Sofosbuvir	44-54	interferon beta 1	Homo sapiens	194-215
29293991-5	2018	By the end of treatment, subjects receiving pegylated interferon, ribavirin, and sofosbuvir (IFN+RBV+SOF) experienced significant decreases in PROs regardless of OST use.	Sofosbuvir	81-91	interferon alpha 1	Homo sapiens	93-96
29442067-0	2018	Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series.	Sofosbuvir	17-27	interferon alpha 1	Homo sapiens	100-110
29743792-14	2018	Further wider-scale studies are needed to evaluate the actual role of IL18 polymorphisms in treatment response with sofosbuvir/daclatasvir.	Sofosbuvir	116-126	interleukin 18	Homo sapiens	70-74
29453451-0	2018	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.	Sofosbuvir	125-135	beta-1,4-galactosyltransferase 1	Homo sapiens	144-147
29450210-3	2018	Methods: Ten phase 3 studies of sofosbuvir-based regimens included ION (ledipasvir/sofosbuvir +- ribavirin for 8, 12, or 24 weeks in GT1), ASTRAL (sofosbuvir/velpatasvir for 12 weeks in GT1-6), and POLARIS (sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir in GT1-6).	Sofosbuvir	32-42	beta-1,4-galactosyltransferase 1	Homo sapiens	186-191
29450210-3	2018	Methods: Ten phase 3 studies of sofosbuvir-based regimens included ION (ledipasvir/sofosbuvir +- ribavirin for 8, 12, or 24 weeks in GT1), ASTRAL (sofosbuvir/velpatasvir for 12 weeks in GT1-6), and POLARIS (sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir in GT1-6).	Sofosbuvir	32-42	beta-1,4-galactosyltransferase 1	Homo sapiens	186-189
28877086-7	2017	Baseline NS3-RASs before retreatment were observed in two patients who failed a sofosbuvir/simeprevir regimen: D168V RAS was detected in a genotype-4 patient, whereas the complex RAS-pattern Q80K, I170V, R155K, D168E was observed in a genotype-1a patient.	Sofosbuvir	80-90	KRAS proto-oncogene, GTPase	Homo sapiens	9-12
29107709-0	2017	IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.	Sofosbuvir	80-90	interferon lambda 4 (gene/pseudogene)	Homo sapiens	0-5
28877086-9	2017	CONCLUSION: These real-life findings indicated a high efficacy of sofosbuvir+NS5A-inihbitors in retreating NS3-experienced patients and also NS5A-experienced patients by using a 24-week course ribavirin-containing regimen.	Sofosbuvir	66-76	KRAS proto-oncogene, GTPase	Homo sapiens	107-110
28657143-10	2017	Serum low-density lipoprotein cholesterol and apolipoprotein B levels were significantly elevated at week 4 in sofosbuvir/ledipasvir-treated patients.	Sofosbuvir	111-121	apolipoprotein B	Homo sapiens	46-62
29188773-10	2017	Mean pharmacokinetic exposure to Sorafenib tosylate 200 mg, Ribavirn and Sofosbuvir at week 8th was 2.1, 1.5,1.2 times greater in CP B than in CP A.	Sofosbuvir	73-83	carboxypeptidase B1	Homo sapiens	130-134
28128521-0	2017	ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.	Sofosbuvir	110-120	inosine triphosphatase	Homo sapiens	0-4
28650160-4	2017	The results showed that compounds 4c-4e and 4m (EC50 = 0.19-0.25 muM) exhibited comparable potency to that of sofosbuvir (EC50 = 0.15 muM) on inhibition of wild-type replicons.	Sofosbuvir	110-120	latexin	Homo sapiens	134-137
28660640-5	2017	AIM: To evaluate the impact of Sofosbuvir/Ledipasvir (SOF/LDV) fixed dose combination for 12 weeks without RBV, in patients with thalassaemia major and HCV Genotype 1 or 4 (GT1/4).	Sofosbuvir	31-41	beta-1,4-galactosyltransferase 1	Homo sapiens	173-178
28109022-0	2017	Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.	Sofosbuvir	136-146	inosine triphosphatase	Homo sapiens	40-62
29188773-8	2017	Child pugh score less then 7 (CP A) in adults during treatment phase (received 12 weeks of Sorafenib tosylate 200 mg, Ribavirn and Sofosbuvir 400 mg once daily) have no side effect while child pugh score 7-9 (CP B) have evidence of hypertension.	Sofosbuvir	131-141	carboxypeptidase A1	Homo sapiens	30-34
28177543-3	2017	The aim of this study is to evaluate changes of transient elastography values as well as FIB-4 and AST to platelet ratio index (APRI) in patients treated with Sofosbuvir-based treatment regimen.	Sofosbuvir	159-169	solute carrier family 17 member 5	Homo sapiens	99-102
28650160-5	2017	Notably, 4c (EC50 = 0.366 muM) was 1.5-fold more potent than sofosbuvir (EC50 = 0.589 muM) on inhibition of S282T mutant replicons.	Sofosbuvir	61-71	latexin	Homo sapiens	86-89
28691797-0	2017	Caught before Released: Structural Mapping of the Reaction Trajectory for the Sofosbuvir Activating Enzyme, Human Histidine Triad Nucleotide Binding Protein 1 (hHint1).	Sofosbuvir	78-88	histidine triad nucleotide binding protein 1	Homo sapiens	114-158
28691797-0	2017	Caught before Released: Structural Mapping of the Reaction Trajectory for the Sofosbuvir Activating Enzyme, Human Histidine Triad Nucleotide Binding Protein 1 (hHint1).	Sofosbuvir	78-88	histidine triad nucleotide binding protein 1	Homo sapiens	160-166
28691797-2	2017	Human Hint1 has been shown to be essential for the metabolic activation of nucleotide antiviral pronucleotides (i.e., proTides), such as the FDA approved hepatitis C drug, sofosbuvir.	Sofosbuvir	172-182	histidine triad nucleotide binding protein 1	Homo sapiens	6-11
27019204-10	2016	CONCLUSIONS: Sofosbuvir + SIM combination therapy without ribavirin is well tolerated and results in high virologic response rates in recurrent HCV GT1 infection after liver transplantation.	Sofosbuvir	13-23	beta-1,4-galactosyltransferase 1	Homo sapiens	148-151
28105744-7	2017	It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures).	Sofosbuvir	200-210	interferon alpha 1	Homo sapiens	16-19
28520377-0	2012	Sofosbuvir Therapy and IFNL4 Genotype Sofosbuvir is an antiviral agent used in the treatment of chronic hepatitis C virus (HCV) infection.	Sofosbuvir	38-48	interferon lambda 4 (gene/pseudogene)	Homo sapiens	23-28
29040986-4	2017	Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group.	Sofosbuvir	189-199	cellular communication network factor 2	Homo sapiens	143-174
29040986-4	2017	Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group.	Sofosbuvir	189-199	cellular communication network factor 2	Homo sapiens	176-180
29040986-8	2017	Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group.	Sofosbuvir	82-92	bone morphogenetic protein 7	Homo sapiens	10-15
29040986-8	2017	Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group.	Sofosbuvir	82-92	cellular communication network factor 2	Homo sapiens	20-24
27054294-3	2016	These values are similar to the EC50 reported for sofosbuvir (2) (0.048 muM) using a similar methodological approach and the same virus subtype.	Sofosbuvir	50-60	latexin	Homo sapiens	72-75
27822709-0	2017	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.	Sofosbuvir	59-69	inosine triphosphatase	Homo sapiens	0-4
27822709-0	2017	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.	Sofosbuvir	59-69	inosine triphosphatase	Homo sapiens	164-186
27822709-11	2017	CONCLUSIONS: ITPA polymorphism influences hemoglobin levels and incidence of RBV dose reduction during sofosbuvir plus RBV therapy.	Sofosbuvir	103-113	inosine triphosphatase	Homo sapiens	13-17
27965153-0	2017	Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil.	Sofosbuvir	45-55	carboxylesterase 2	Homo sapiens	23-41
28085003-2	2017	In Brazil, direct-acting anti-HCV therapy has recently changed with the introduction of interferon (IFN)-free regimens with sofosbuvir; however, the presence of resistant variants on clinical outcomes remains unknown.	Sofosbuvir	124-134	interferon alpha 1	Homo sapiens	88-105
26990023-6	2016	A road map strategy using rapid virological response to guide use of BOC/PR and sofosbuvir/PR had the most favorable incremental cost-effective ratio ($US27 782) relative to BOC/PR.	Sofosbuvir	80-90	BOC cell adhesion associated, oncogene regulated	Homo sapiens	174-180
27382805-4	2016	In 2014, the U.S. Food and Drug Administration approved ledipasvir plus sofosbuvir to treat the chronic infection, the first IFN- and ribavirin-free approved treatment.	Sofosbuvir	72-82	interferon alpha 1	Homo sapiens	125-129
27276081-8	2016	RESULTS: Sofosbuvir/ledipasvir was cost-effective in treatment-experienced patients with an ICER of US$21,612.	Sofosbuvir	9-19	cAMP responsive element modulator	Homo sapiens	92-96
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	68-78	interferon alpha 1	Homo sapiens	50-53
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	68-78	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	111-115
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	80-83	interferon alpha 1	Homo sapiens	50-53
26945356-3	2016	The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry.	Sofosbuvir	80-83	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	111-115
26788529-3	2015	In the second case of a patient with prediabetes, ledipasvir/sofosbuvir appeared to increase insulin resistance.	Sofosbuvir	61-71	insulin	Homo sapiens	93-100
26558305-3	2016	With the production of generic formulations of sofosbuvir, we anticipate this regimen leading the first wave for widespread, IFN-free treatment and becoming first line for all genotypes (including genotype 1) for much of the world-in particular in developing and middle income countries.	Sofosbuvir	47-57	interferon alpha 1	Homo sapiens	125-129
26595724-12	2016	In the base-case analysis, among patients receiving 8 or 12 weeks of sofosbuvir-ledipasvir treatment, treating all fibrosis stages compared with treating stages F3 and F4 adds 0.73 QALYs and $28,899, for an ICER of $39,475 per QALY gained.	Sofosbuvir	69-79	cAMP responsive element modulator	Homo sapiens	207-211
26595724-18	2016	A 46% reduction in cost of sofosbuvir-ledipasvir therapy decreases the ICER for treating at all fibrosis stages by 48%.	Sofosbuvir	27-37	cAMP responsive element modulator	Homo sapiens	71-75
27293923-3	2016	Following successful therapy with sofosbuvir, simeprevir, and ribavirin, her insulin requirements decreased and her glycosylated hemoglobin (HgA1c) normalized despite weight gain.	Sofosbuvir	34-44	insulin	Homo sapiens	77-84
26770924-13	2015	Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy.	Sofosbuvir	106-116	interferon alpha 1	Homo sapiens	123-126
26563720-2	2015	Antiviral regimens including sofosbuvir are associated with success rates >90%, even in the case of "difficult-to-treat" patients such as subjects with liver cirrhosis as well as prior null response to IFN and ribavirin.	Sofosbuvir	29-39	interferon alpha 1	Homo sapiens	205-208
26280786-0	2015	Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.	Sofosbuvir	11-21	apolipoprotein E	Homo sapiens	91-105
26280786-2	2015	Our aim was to evaluate changes in the apolipoprotein profile of patients with chronic hepatitis C during and after successful cure with ledipasvir and sofosbuvir (LDV/SOF) with and without ribavirin (RBV).	Sofosbuvir	152-162	apolipoprotein E	Homo sapiens	39-53
26096332-2	2015	Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).	Sofosbuvir	30-40	beta-1,4-galactosyltransferase 1	Homo sapiens	223-226
26596942-6	2016	In contrast, NI containing multiple ribose modifications, including the active forms of mericitabine and sofosbuvir, were poor substrates for PolRMT and did not show mitochondrial toxicity in cells.	Sofosbuvir	105-115	RNA polymerase mitochondrial	Homo sapiens	142-148
26596948-10	2016	Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir.	Sofosbuvir	13-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	69-101
26596948-10	2016	Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir.	Sofosbuvir	13-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	103-107
26596948-10	2016	Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir.	Sofosbuvir	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	116-130
25847572-11	2015	In genotype 3, sofosbuvir had a weighted ICER of $18 761/QALY.	Sofosbuvir	15-25	cAMP responsive element modulator	Homo sapiens	41-45
26488159-9	2015	Contraindicated associations/potential interactions were expected between cART and respectively sofosbuvir (0.2%/0%), sofosbuvir/ledipasvir (0.2%/67.6%), daclatasvir (0%/49.4%), ombitasvir/boosted paritaprevir (with or without dasabuvir) (34.4%/52.2%) and simeprevir (78.8%/0%).	Sofosbuvir	96-106	CART prepropeptide	Homo sapiens	74-78
26096332-2	2015	Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).	Sofosbuvir	42-45	beta-1,4-galactosyltransferase 1	Homo sapiens	223-226
26057627-1	2015	UNLABELLED: Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3.	Sofosbuvir	21-31	proline rich coiled-coil 2A	Homo sapiens	80-87
26391423-2	2015	The aim of this continuing analysis is evaluation of the impact of an IFN-free sofosbuvir (SOF)-based therapy in HCV-infected liver transplant recipients.	Sofosbuvir	79-89	interferon alpha 1	Homo sapiens	70-73
26391423-2	2015	The aim of this continuing analysis is evaluation of the impact of an IFN-free sofosbuvir (SOF)-based therapy in HCV-infected liver transplant recipients.	Sofosbuvir	91-94	interferon alpha 1	Homo sapiens	70-73
26209383-3	2015	We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy.	Sofosbuvir	20-30	KRAS proto-oncogene, GTPase	Homo sapiens	161-164
25775312-11	2015	RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY.	Sofosbuvir	31-41	cAMP responsive element modulator	Homo sapiens	101-105
25820703-11	2015	RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients.	Sofosbuvir	43-53	cAMP responsive element modulator	Homo sapiens	35-39
25820703-12	2015	RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively.	Sofosbuvir	45-55	cAMP responsive element modulator	Homo sapiens	37-41
25820703-12	2015	RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively.	Sofosbuvir	192-202	cAMP responsive element modulator	Homo sapiens	37-41
25891129-6	2015	This analysis evaluates the cost - effectiveness of sofosbuvir for GTs 1-6 in Italy.	Sofosbuvir	52-62	beta-1,4-galactosyltransferase 1	Homo sapiens	67-74
27202476-0	2014	Costs Per Successfully Treated Patient with Sofosbuvir in GT1 HCV.	Sofosbuvir	44-54	beta-1,4-galactosyltransferase 1	Homo sapiens	58-61
25458777-4	2014	Clinical development of sofosbuvir has been conducted with the strategy of positioning it as the backbone drug of several combination regimes, including triple therapy with pegylated interferon and ribavirin, but also IFN-free regimen with ribavirin alone as well as with complementary direct antiviral agents directed against other virus targets.	Sofosbuvir	24-34	interferon alpha 1	Homo sapiens	218-221
25458781-3	2014	Sofosbuvir induced sustained virologic response in 91% of 23 HIV/HCV coinfected persons treated in combination with ribavirin and pegylated interferon, in 83% of 497 treated in combination with ribavirin and in all 50 patients infected with HCV GT1 treated in combination with ledipasvir and ribavirin.	Sofosbuvir	0-10	beta-1,4-galactosyltransferase 1	Homo sapiens	245-248
25529083-3	2015	In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non-CC IFNL3 genotype have been associated with a poorer response.	Sofosbuvir	74-84	interferon alpha 1	Homo sapiens	47-50
25364884-1	2014	BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN.	Sofosbuvir	49-59	interferon alpha 1	Homo sapiens	28-31
25364884-1	2014	BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN.	Sofosbuvir	49-59	interferon alpha 1	Homo sapiens	206-209
24713186-2	2014	Our aim was to assess PROs during treatment with an IFN-free regimen [sofosbuvir (SOF)+ribavirin (RBV)].	Sofosbuvir	70-80	interferon alpha 1	Homo sapiens	52-55
24848437-4	2014	However, an IFN-free combination (sofosbuvir and ribavirin) has been recently approved for genotypes 2 and 3 patients with many other drugs in preclinical and clinical development.	Sofosbuvir	34-44	interferon alpha 1	Homo sapiens	12-15
25040927-0	2014	Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients.	Sofosbuvir	68-78	calcineurin binding protein 1	Homo sapiens	8-29
24713186-2	2014	Our aim was to assess PROs during treatment with an IFN-free regimen [sofosbuvir (SOF)+ribavirin (RBV)].	Sofosbuvir	82-85	interferon alpha 1	Homo sapiens	52-55
25002352-4	2014	The NS3/4A inhibitor simeprevir and NS5B inhibitor sofosbuvir have recently been licensed and can reduce the length of antiviral treatment, improve response rates, and allow for interferon-free regimens for some HCV genotypes.	Sofosbuvir	51-61	KRAS proto-oncogene, GTPase	Homo sapiens	4-7
24677184-1	2014	UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.	Sofosbuvir	293-303	interferon alpha 1	Homo sapiens	227-230
24677184-1	2014	UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.	Sofosbuvir	340-350	interferon alpha 1	Homo sapiens	227-230
24289735-12	2014	Sofosbuvir will first be available in association with PEG-IFN/RBV.	Sofosbuvir	0-10	interferon alpha 1	Homo sapiens	59-62
24367041-0	2014	IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.	Sofosbuvir	113-123	interferon lambda 4 (gene/pseudogene)	Homo sapiens	0-5
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	Sofosbuvir	48-58	interferon lambda 4 (gene/pseudogene)	Homo sapiens	75-80
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	Sofosbuvir	48-58	interferon lambda 3	Homo sapiens	252-263
24367041-3	2014	We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies.	Sofosbuvir	48-58	interferon alpha 1	Homo sapiens	267-276
24822024-3	2014	Sofosbuvir (SOF) is the first compound to enter the market with IFN-free combination regimens; it belongs to the nucleotide inhibitors of viral polymerase NS5B and acts as a chain terminator during the HCV replication process, exhibiting pan-genotypic antiviral activity with a high barrier to resistance.	Sofosbuvir	0-10	interferon alpha 1	Homo sapiens	64-67
24822024-3	2014	Sofosbuvir (SOF) is the first compound to enter the market with IFN-free combination regimens; it belongs to the nucleotide inhibitors of viral polymerase NS5B and acts as a chain terminator during the HCV replication process, exhibiting pan-genotypic antiviral activity with a high barrier to resistance.	Sofosbuvir	12-15	interferon alpha 1	Homo sapiens	64-67
24333184-3	2014	The aim is to report the HRQL of patients who participated in clinical trials of sofosbuvir (SOF) for CH-C.	Sofosbuvir	81-91	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	102-106
24333184-4	2014	METHODS: CH-C patients were treated with sofosbuvir (SOF), pegylated interferon (PegIFN), ribavirin (RBV), or placebo in different combinations and duration (POSITRON, FISSION, FUSION, and NEUTRINO phase III trials).	Sofosbuvir	41-51	solute carrier family 4 member 1 (Diego blood group)	Homo sapiens	9-13
24387618-6	2014	In genotype 1 (G1) patients, the addition of sofosbuvir to peginterferon plus ribavirin yielded sustained virological response rates at week 12 after discontinuation of treatment (SVR12) of about 90% with slightly lower levels in G1b and in patients with cirrhosis, but with no major impact of IL28B genotype, high viral load, body mass index (BMI), alanine aminotransferase (ALT) or race/ethnicity.	Sofosbuvir	45-55	interferon lambda 3	Homo sapiens	294-299
24387618-6	2014	In genotype 1 (G1) patients, the addition of sofosbuvir to peginterferon plus ribavirin yielded sustained virological response rates at week 12 after discontinuation of treatment (SVR12) of about 90% with slightly lower levels in G1b and in patients with cirrhosis, but with no major impact of IL28B genotype, high viral load, body mass index (BMI), alanine aminotransferase (ALT) or race/ethnicity.	Sofosbuvir	45-55	glutamic--pyruvic transaminase	Homo sapiens	350-374
24373081-3	2014	Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1.	Sofosbuvir	40-50	interferon alpha 1	Homo sapiens	21-24
24289735-13	2014	Sofosbuvir appears to be a key compound and a backbone for future IFN free treatment regimen.	Sofosbuvir	0-10	interferon alpha 1	Homo sapiens	66-69
25165553-7	2013	Sofosbuvir has highly potent antiviral activity across all genotypes in association with pegylated interferon (IFN) and ribavirin (PR), thus allowing shortened treatment duration.	Sofosbuvir	0-10	interferon alpha 1	Homo sapiens	111-114
24254131-6	2013	In particular, an IFN sparing regimen of sofosbuvir/RBV may become available in 2014.	Sofosbuvir	41-51	interferon alpha 1	Homo sapiens	18-21
33768560-0	2021	Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.	Sofosbuvir	87-97	interferon lambda 3	Homo sapiens	20-35
33768560-3	2021	We aimed to evaluate the usefulness of the reference single nucleotide polymorphism (rs12979860) interleukin 28B (CC genotype) for predicting sustained virological response to sofosbuvir plus daclatasvir in Egyptian patients infected with HCV-4.	Sofosbuvir	176-186	interferon lambda 3	Homo sapiens	97-112
33768560-9	2021	WHAT IS NEW AND CONCLUSION: Our results suggest that IL28B genotype contributes to the prediction of response to sofosbuvir plus daclatasvir.	Sofosbuvir	113-123	interferon lambda 3	Homo sapiens	53-58
33800884-5	2021	A double mutant in the NS5 gene (V360L/V607I) emerged in 3 independent experiments at 40-80 microM sofosbuvir resulting in a 3.9 +- 0.9-fold half- maximal inhibitory concentration (IC50) shift with respect to the wild type (WT) virus.	Sofosbuvir	99-109	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-26
33800884-9	2021	By a combination of sequence analysis, phenotypic susceptibility testing, and molecular modeling, we characterized a double ZIKV NS5 mutant with decreased sofosbuvir susceptibility.	Sofosbuvir	155-165	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	129-132
34728543-8	2021	CONCLUSION: An increase in the baseline level of alanine aminotransferase was found to play a role in the reduction in the quality of life of patients with chronic hepatitis C who had undergone ledipasvir/sofosbuvir therapy.	Sofosbuvir	205-215	glutamic--pyruvic transaminase	Homo sapiens	49-73
34960758-5	2021	We also demonstrated that IFNalpha combinations with sofosbuvir, telaprevir, NITD008, ribavirin, pimodivir, or lamivudine were effective against HCV, HEV, FLuAV, or HIV at lower concentrations, compared to monotherapies.	Sofosbuvir	53-63	interferon alpha 1	Homo sapiens	26-34
34957030-3	2021	Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable in China in 2020.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	24-31
33895411-0	2021	Treatment of viral hepatitis C Genotype 1 and 2 by the Sofosbuvir and Ledipasvir with or without Ribavirin combination: a possible eventual to pangenotypic treatment in a low-income country?	Sofosbuvir	55-65	c genotype 1 and 2	None	29-47
34511496-0	2021	Circulating macrophage inflammatory protein-1beta/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.	Sofosbuvir	74-84	C-C motif chemokine ligand 4	Homo sapiens	12-49
35023081-12	2022	CONCLUSION: The results indicated that the absorptive clearance of Sofosbuvir was site dependent and associated with the content of P-glycoprotein, in addition to the expected drug interactions that can occur in polymedicated hepatitis C virus (HCV) infected patients.	Sofosbuvir	67-77	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
35185356-8	2022	The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection.	Sofosbuvir	73-83	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	38-42
35185356-8	2022	The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection.	Sofosbuvir	73-83	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	173-177
35571427-0	2022	Sofosbuvir and ledipasvir decreased nephrotic syndrome caused by IgA nephropathy with a membranoproliferative pattern of injury in hepatitis C virus-induced cirrhosis: a case report.	Sofosbuvir	0-10	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	65-68
35571427-6	2022	Twelve-week sofosbuvir and ledipasvir therapy successfully eradicated HCV in this decompensated cirrhosis patient and resulted in partial remission of IgAN.	Sofosbuvir	12-22	IGAN1	Homo sapiens	151-155
35107877-4	2022	Specifically studied were variants predicted to impair CES1-dependent production of sofosbuvir"s active metabolite, interferon-lambda signaling variants expected to impact a patient"s immune response to the virus, and an HLA variant associated with increased spontaneous and treatment-induced viral clearance.	Sofosbuvir	84-94	carboxylesterase 1	Homo sapiens	55-59
34216889-4	2021	Successive interactions between RdRp (nsp12 alone or in complex with cofactors nsp7-8) and viral RNA demonstrated that the binding affinity values remained the same, but the sites of interaction of RdRp (highly conserved for homologous sequences from different organisms) were altered in the presence of selected antiviral drugs such as Remdesivir, and Sofosbuvir.	Sofosbuvir	353-363	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	32-36
34216889-4	2021	Successive interactions between RdRp (nsp12 alone or in complex with cofactors nsp7-8) and viral RNA demonstrated that the binding affinity values remained the same, but the sites of interaction of RdRp (highly conserved for homologous sequences from different organisms) were altered in the presence of selected antiviral drugs such as Remdesivir, and Sofosbuvir.	Sofosbuvir	353-363	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	79-85
34216889-4	2021	Successive interactions between RdRp (nsp12 alone or in complex with cofactors nsp7-8) and viral RNA demonstrated that the binding affinity values remained the same, but the sites of interaction of RdRp (highly conserved for homologous sequences from different organisms) were altered in the presence of selected antiviral drugs such as Remdesivir, and Sofosbuvir.	Sofosbuvir	353-363	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	198-202
34216889-5	2021	The antiviral drug Sofosbuvir reduced the number of hydrogen bonds formed between RdRp and RNA.	Sofosbuvir	19-29	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	82-86
35510477-3	2022	The results reveal a comparable binding affinity of sofosbuvir, galidesivir, ribavirin and remdesivir compared with the physiological nucleotide triphosphates against R. oryzae RdRp as well as the SARS-CoV-2 RdRp as reported before.	Sofosbuvir	52-62	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	177-181
35510477-3	2022	The results reveal a comparable binding affinity of sofosbuvir, galidesivir, ribavirin and remdesivir compared with the physiological nucleotide triphosphates against R. oryzae RdRp as well as the SARS-CoV-2 RdRp as reported before.	Sofosbuvir	52-62	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	208-212
32338164-6	2021	The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.	Sofosbuvir	38-48	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	171-175
33857308-0	2021	Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.	Sofosbuvir	172-182	hepatitis c genotypes 1, 2, 3, and 4	None	77-113
33389441-3	2022	In this study, detailed molecular docking and dynamics simulations are used to evaluate the binding affinity of a clinically approved drug, sofosbuvir, with the solved structure of the viral protein RNA-dependent RNA polymerase (RdRp) and compare it to the clinically approved drug, Remdesivir.	Sofosbuvir	140-150	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	229-233
33463051-0	2021	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.	Sofosbuvir	0-10	insulin	Homo sapiens	32-39
33463051-0	2021	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation.	Sofosbuvir	0-10	insulin receptor substrate 1	Homo sapiens	63-67
33693066-7	2021	In this study, we have screened a library of compounds, containing approved RdRp inhibitor drugs that were or in use to treat other viruses (favipiravir, sofosbuvir, ribavirin, lopinavir, tenofovir, ritonavir, galidesivir and remdesivir) and their structural analogues, in order to identify potential inhibitors of SARS-CoV-2 RdRp.	Sofosbuvir	154-164	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	76-80
33389441-9	2022	The interaction of SARS-CoV-2 RdRp as a target with the active form of sofosbuvir as a ligand demonstrates binding effectiveness.	Sofosbuvir	71-81	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	30-34
33389441-11	2022	Sofosbuvir was found to bind nsp12 with comparable binding energies to that of Remdesivir, which has been reported for its potential against COVID-19 RdRp and is currently approved by the FDA.	Sofosbuvir	0-10	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	150-154
33442459-4	2020	CASE SUMMARY: We present the cases of six liver transplant recipients who had previous treatment failure with sofosbuvir-based DAA therapy prior to transplantation and who then received SOF/VEL/VOX after transplant.	Sofosbuvir	110-120	small integral membrane protein 1 (Vel blood group)	Homo sapiens	186-197
33287144-2	2020	In recent years, RdRp has emerged as an optimal target for the development of antiviral drugs, as demonstrated by recent approvals of sofosbuvir and remdesivir against Hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respectively.	Sofosbuvir	134-144	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	17-21
32656649-3	2020	Here, we report three patients with HCV NS5A-P32del infection who were treated with sofosbuvir, velpatasvir plus ribavirin (SOF/VEL + RBV) in a real-world setting.	Sofosbuvir	84-94	small integral membrane protein 1 (Vel blood group)	Homo sapiens	128-131
32885325-0	2020	A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNalpha + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.	Sofosbuvir	118-128	insulin	Homo sapiens	185-192
32692185-4	2020	Here, we used polymerase extension experiments to demonstrate that the active triphosphate form of Sofosbuvir (an FDA-approved hepatitis C drug) is incorporated by SARS-CoV-2 RdRp and blocks further incorporation.	Sofosbuvir	99-109	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	175-179
32816249-10	2020	Age > 65 years, baseline eGFR, and ribavirin-containing regimens were independent risk factors of eGFR decline during and after SOF-based treatment.	Sofosbuvir	128-131	epidermal growth factor receptor	Homo sapiens	98-102
33127459-0	2020	Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.	Sofosbuvir	126-136	interferon lambda 4 (gene/pseudogene)	Homo sapiens	0-19
33127459-2	2020	So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration.	Sofosbuvir	94-104	interferon lambda 4 (gene/pseudogene)	Homo sapiens	47-52
33127459-2	2020	So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration.	Sofosbuvir	106-109	interferon lambda 4 (gene/pseudogene)	Homo sapiens	47-52
32804853-1	2021	OBJECTIVES: To evaluate the effect of generic sofosbuvir and daclatasvir (SOF/DCV) treatment on the glycemic state and insulin resistance as well as lipid profiles of those who achieved sustained virological response (SVR) in diabetic chronic hepatitis C virus (CHC) patients.	Sofosbuvir	46-56	insulin	Homo sapiens	119-126
32804853-1	2021	OBJECTIVES: To evaluate the effect of generic sofosbuvir and daclatasvir (SOF/DCV) treatment on the glycemic state and insulin resistance as well as lipid profiles of those who achieved sustained virological response (SVR) in diabetic chronic hepatitis C virus (CHC) patients.	Sofosbuvir	74-77	insulin	Homo sapiens	119-126
32387040-5	2020	Coronaviruses are a family of positive-strand RNA viruses with conserved polymerase, so SARS-CoV-2 RdRp is very likely to be effectively inhibited by sofosbuvir.	Sofosbuvir	150-160	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	99-103
32511320-3	2020	Here, using polymerase extension experiments, we have demonstrated that the active triphosphate form of Sofosbuvir (a key component of the FDA approved hepatitis C drug EPCLUSA), is incorporated by SARS-CoV-2 RdRp, and blocks further incorporation.	Sofosbuvir	104-114	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	209-213
32222463-0	2020	Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.	Sofosbuvir	23-33	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	111-115
32222463-6	2020	KEY FINDINGS: The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp.	Sofosbuvir	78-88	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	183-187
32766479-9	2020	Patients with low baseline C4 had improved proteinuria, urinary neutrophil gelatinase-associated lipocalin, and interleukin-18 after ledipasvir and sofosbuvir treatment.	Sofosbuvir	148-158	complement C4A (Rodgers blood group)	Homo sapiens	27-29
32345577-1	2020	Sofosbuvir (SOF) is a nucleotide prodrug which has been used as a backbone for the clinical treatment of hepatitis C viral infection.	Sofosbuvir	0-10	sof	None	12-15
32486887-0	2020	Peripheral Expression of CXCL10 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin.	Sofosbuvir	82-92	C-X-C motif chemokine ligand 10	Homo sapiens	25-31
32486887-6	2020	In this study we analyzed the expression levels of CXCL10 mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response.	Sofosbuvir	162-172	C-X-C motif chemokine ligand 10	Homo sapiens	51-57
32419838-3	2020	Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency.	Sofosbuvir	153-163	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	43-47
31863490-8	2020	We have studied the expression levels of one of these antiviral effectors, TRIM22 in response to sofosbuvir (SOF) and daclatasvir (DAC) in combination with RBV, using quantitative PCR in the peripheral blood mononuclear cells (PBMCs) of HCV-infected patients.	Sofosbuvir	97-107	tripartite motif containing 22	Homo sapiens	75-81
31863490-8	2020	We have studied the expression levels of one of these antiviral effectors, TRIM22 in response to sofosbuvir (SOF) and daclatasvir (DAC) in combination with RBV, using quantitative PCR in the peripheral blood mononuclear cells (PBMCs) of HCV-infected patients.	Sofosbuvir	109-112	tripartite motif containing 22	Homo sapiens	75-81
32562705-2	2020	We previously demonstrated that five nucleotide analogues inhibit the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), including the active triphosphate forms of Sofosbuvir, Alovudine, Zidovudine, Tenofovir alafenamide and Emtricitabine.	Sofosbuvir	161-171	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	111-115
32316635-0	2020	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes.	Sofosbuvir	0-10	epidermal growth factor receptor	Homo sapiens	21-25
32316635-4	2020	We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation.	Sofosbuvir	29-39	epidermal growth factor receptor	Homo sapiens	96-100
32316635-4	2020	We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation.	Sofosbuvir	41-44	epidermal growth factor receptor	Homo sapiens	96-100
32088688-0	2020	Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.	Sofosbuvir	14-24	interleukin 6	Homo sapiens	40-53
32138687-0	2020	Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.	Sofosbuvir	39-49	c genotype 1, 2, 3, 4, or 6	None	112-139
32138687-1	2020	BACKGROUND: We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.	Sofosbuvir	67-77	genotypes 1, 2, 3, 4, or 6	None	189-215
32189931-1	2020	Background: Our data is one of the earliest study from the Indian subcontinent on Velpatasvir/Sofosbuvir (VEL/SOF) combination in chronic hepatitis C (CHC).	Sofosbuvir	94-104	small integral membrane protein 1 (Vel blood group)	Homo sapiens	106-113
32154326-1	2020	Background: Clinical trials show high efficacy of sofosbuvir/velpatasvir (SOF/VEL), but there are limited data from "real-world" settings.	Sofosbuvir	50-60	small integral membrane protein 1 (Vel blood group)	Homo sapiens	78-81
32088688-0	2020	Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.	Sofosbuvir	14-24	interferon lambda 4 (gene/pseudogene)	Homo sapiens	104-124
32083035-0	2020	Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.	Sofosbuvir	103-113	lipocalin 2	Homo sapiens	6-48
32083035-0	2020	Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.	Sofosbuvir	103-113	lipocalin 2	Homo sapiens	50-54
32083035-5	2020	Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen.	Sofosbuvir	159-169	lipocalin 2	Homo sapiens	48-90
32083035-5	2020	Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen.	Sofosbuvir	159-169	lipocalin 2	Homo sapiens	92-96
31433303-1	2019	BACKGROUND AND AIMS: Sofosbuvir/Velpatasivr/Voxilaprevir (SOF/VEL/VOX) is approved for retreatment of hepatitis C (HCV) patients with a previous failure to direct-acting antivirals (DAA), however real-life data are limited.	Sofosbuvir	21-31	small integral membrane protein 1 (Vel blood group)	Homo sapiens	62-65
32368983-2	2020	OBJECTIVE: The aim of the current study was to investigate the impact of IL-28B rs12979860 and rs8099917, and, ICAM-1 rs281437 SNPs on response to treatment with sofosbuvir + Daclatsvir +- Ribavirin, among HCV-infected Egyptian patients.	Sofosbuvir	162-172	intercellular adhesion molecule 1	Homo sapiens	111-117
31368531-4	2019	AIM: The current study aimed to investigate the relation between miRNA-21 expression profiles, transforming growth factor beta (TGF-beta) serum levels and response to treatment with the new direct antiviral drugs (sofosbuvir + daclatasvir +- ribavirin), among HCV infected Egyptian patients.	Sofosbuvir	214-224	microRNA 21	Homo sapiens	65-73
31355968-0	2019	Retreatment with elbasvir, grazoprevir, sofosbuvir +- ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.	Sofosbuvir	40-50	beta-1,4-galactosyltransferase 1	Homo sapiens	89-92
31203153-19	2019	LAY SUMMARY: Treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks is the current recommendation for the 5% of patients infected with HCV who do not achieve eradication of the virus under treatment with direct-acting antivirals.	Sofosbuvir	28-38	small integral membrane protein 1 (Vel blood group)	Homo sapiens	65-76
31173550-1	2019	In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients.	Sofosbuvir	67-77	peg-inf/rbv	None	180-191
31173550-1	2019	In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG-INF/RBV)-experienced chronic hepatitis C virus (HCV) patients.	Sofosbuvir	79-82	peg-inf/rbv	None	180-191
31012179-1	2019	Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	41-44